NCT06947928 2026-04-17Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell CarcinomaTuHURA Biosciences, Inc.Phase 2/3 Recruiting118 enrolled
NCT04787744 2026-04-08VA STARPORTVA Office of Research and DevelopmentPhase 2/3 Recruiting464 enrolled
NCT06989437 2026-04-08A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and FatiguePfizerPhase 2/3 Recruiting982 enrolled
NCT06506955 2026-04-03Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.Taiho Oncology, Inc.Phase 2/3 Enrolling by invitation15 enrolled
NCT07509398 2026-04-03FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal CancerShanghai 10th People's HospitalPhase 2/3 Not yet recruiting220 enrolled
NCT06581406 2026-04-02A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaReplimune, Inc.Phase 2/3 Recruiting280 enrolled